RESUMEN
Flurbiprofen and ibuprofen were compared in a six-week double-blind randomized study in 208 patients with rheumatoid arthritis. Daily dosages were 120 mg flurbiprofen and 2400 mg ibuprofen for six weeks. Both drugs were effective in providing partial control of RA symptoms. Either or both drugs produced statistically significant improvement in mean values of time of onset of fatigue, grip strength and tender and swollen joint counts. All other standard endpoints of efficacy (except ESR) were improved but not at a statistically significant level. Slightly more than half of the patients improved during the trial. There was no statistically significant difference in the efficacy of the drugs. The incidence of side effects was low with both drugs. Most side effects were related to gastrointestinal tract irritation.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Flurbiprofeno/uso terapéutico , Ibuprofeno/uso terapéutico , Fenilpropionatos/uso terapéutico , Propionatos/uso terapéutico , Artritis Reumatoide/fisiopatología , Ensayos Clínicos como Asunto , Evaluación de Medicamentos , Femenino , Flurbiprofeno/efectos adversos , Humanos , Ibuprofeno/efectos adversos , Masculino , Persona de Mediana Edad , Cooperación del PacienteRESUMEN
Flurbiprofen and ibuprofen, two propionic acid derivatives with anti-inflammatory and analgesic activity, were compared in a double-blind multiclinic study in 195 patients with osteoarthritis of the peripheral joints. The patients were given 80 mg/day flurbiprofen or 1600 mg/day ibuprofen for six weeks. Pain, subjective evaluation and functional tests improved significantly in both groups. There were no statistically significant differences between the two treatments in any of the responses. Gastro-intestinal side-effects, generally mild, developed in 5-6% of the patients.
Asunto(s)
Flurbiprofeno/uso terapéutico , Ibuprofeno/uso terapéutico , Osteoartritis/tratamiento farmacológico , Fenilpropionatos/uso terapéutico , Propionatos/uso terapéutico , Anciano , Ensayos Clínicos como Asunto , Evaluación de Medicamentos , Femenino , Flurbiprofeno/efectos adversos , Humanos , Ibuprofeno/efectos adversos , Masculino , Persona de Mediana EdadRESUMEN
In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo. Each treatment was given for four weeks. Considering relief of pain, ability to function, and general well-being, the patients preferred drug to placebo, usually by a statistically significant margin. Combined results showed no significant differences between ibuprofen and aspirin. Patients' evaluations of exercise-related pain, ability to perform a selected activity, and total discomfort and disability, and physicians' evaluations of discomfort and disability, all favored drug over placebo, and the differences were significant for a number of endpoints. The results indicated ibuprofen, 1,800 mg/day, offers about the same antiarthritic benefit as aspirin, 3,600 mg/day. Both drugs are superior to placebo. The incidence of gastrointestinal complaints with ibuprofen was similar to that with placebo and significantly lower than that with aspirin.